There remains a compelling need for the development of treatments for unresectable melanoma. Agents that stimulate the innate immune response could provide advantages for cell-based therapies. However, there are conflicting reports concerning whether toll-like receptor (TLR) signaling controls tumor growth. The objective of this study was to evaluate the effect of intralesional administration of a TLR7 agonist in melanoma therapy. B16cOVA melanoma was implanted to TLR7 -/mice to evaluate the roles of stromal TLR7 on melanoma growth. To capitalize on the potential deleterious effects of TLR7 stimulation on the tumor growth, we injected melanoma tumor nodules with a newly developed and potent TLR7 agonist. B16 melanoma nodules expanded more rapidly in TLR7-deficient and MyD88 -/mice compared with TLR9 -/and wild type mice. Repeated injections with low doses of unconjugated TLR7 agonist were more effective at attenuating nodule size than a single high dose injection. To improve the efficacy we conjugated the agonist to phospholipid or phospholipids-polyethylene glycol, which retained TLR7 specificity. The phospholipid conjugate was indeed more effective in reducing lesion size. Furthermore, intralesional administration of the phospholipid TLR7 agonist conjugate enhanced the antimelanoma effects of systemic treatment with interleukin (IL)-2 and prolonged the survival of mice compared with IL-2 alone. Our study showed that:
There remains a compelling need for the development of treatments for unresectable melanoma. Agents that stimulate the innate immune response could provide advantages for cell-based therapies. However, there are conflicting reports concerning whether toll-like receptor (TLR) signaling controls tumor growth. The objective of this study was to evaluate the effect of intralesional administration of a TLR7 agonist in melanoma therapy. B16cOVA melanoma was implanted to TLR7 -/mice to evaluate the roles of stromal TLR7 on melanoma growth. To capitalize on the potential deleterious effects of TLR7 stimulation on the tumor growth, we injected melanoma tumor nodules with a newly developed and potent TLR7 agonist. B16 melanoma nodules expanded more rapidly in TLR7-deficient and MyD88 -/mice compared with TLR9 -/and wild type mice. Repeated injections with low doses of unconjugated TLR7 agonist were more effective at attenuating nodule size than a single high dose injection. To improve the efficacy we conjugated the agonist to phospholipid or phospholipids-polyethylene glycol, which retained TLR7 specificity. The phospholipid conjugate was indeed more effective in reducing lesion size. Furthermore, intralesional administration of the phospholipid TLR7 agonist conjugate enhanced the antimelanoma effects of systemic treatment with interleukin (IL)-2 and prolonged the survival of mice compared with IL-2 alone. Our study showed that: (1) TLR7/MyD88 signaling in the stroma is involved in melanoma growth; and (2) intralesional administration of a TLR7 agonist reduces the growth of melanoma nodules and enhances the antimelanoma effects of IL-2. 
Introduction
Melanoma of the skin is one of the most clinically important skin and soft tissue malignancies. If properly diagnosed and treated in the early stages, its prognosis and outcome are uniformly favorable. However, advanced melanoma has the highest per-death loss of years of potential life expectancy except for adult leukemia [1, 2] . Metastatic melanoma has been found to be susceptible to systemic immunologic therapy including adoptive cell therapy, immune checkpoint modulation, and cytokine therapy. Systemic interleukin (IL)-2 therapy induces complete remission in the minority of patients and is approved for the treatment of unresectable melanoma, but has substantial morbidity that limits the application to a selected group of patients [2, 3] . Intralesional therapy with inflammatory stimulants, including toll-like receptor (TLR) agonists, has been variably successful [4] .
Topical treatment with TLR7 agonist, imiquimod, was approved by the Food and Drug Administration (FDA) in 1997 for use in treating viral warts and some nonmelanoma cutaneous tumors [5] [6] [7] . The TLRs are a key part of the innate immune system, and are expressed by diverse cell types including macrophages, dendritic cells, lymphocytes, and epithelial cells [8, 9] . TLRs recognize both common ligands in microbes and endogenous host molecules with similar molecular structures. TLRs interact with lipid structures (TLR2 and TLR4) [10, 11] , proteins (TLR4, TLR5, and TLR11) [12] [13] [14] , and nucleic acids (TLR3, TLR7, TLR8, and TLR9) [15, 16] . TLR7 recognizes naturally occurring single stranded RNA and synthetic low molecular weight ligands, including imidazoquinolines and purine-like molecules [8, 17, 18] . All TLRs, except TLR3, signal through the myeloid differentiation primary response gene 88 (MyD88) adapter protein, resulting in activation of NF-kB and increased transcription of the inflammatory cytokine genes that it regulates [19] .
Earlier, we reported a series of TLR7 agonists conjugated with phospholipids, or phospholipid-polyethylene glycol (PEG), through a N-hydroxysuccinimide (NHS) activated ester group to form amide linkages [20] . Here we show that TLR7 deficiency in the tumor microenvironment enhances growth of subcutaneous B16 melanoma nodules in mice, supporting the rationale that locally administering a TLR7 agonist might suppress tumor growth. Systemic administration of the phospholipid and phospholipid-PEG TLR7 conjugates induced prolonged elevations in serum proinflammatory cytokine levels, compared with the unmodified TLR7 agonist [20] . Prolonged delivery utilizing repeated intratumoral injections of the activated parent compound capable of in-situ coupling with free amines, designated 1V199, into subcutaneous B16 melanoma nodules was more effective at limiting growth than a single injection or injection of a corresponding noncoupling compound. We hypothesized that the phospholipid (1V270) and phospholipid-PEG TLR7 (1V285) conjugates would have protracted activity between injections and enhanced efficacy. Intralesional administration of one of the phospholipid conjugate, 1V270, significantly delayed the tumor growth. We then tested for potential synergy between systemic administration of the T cell cytokine, IL-2, and local injection of the innate immune agonist, 1V270. Repeated intratumoral injections of 1V270 improved the antimelanoma effect of concomitant systemic IL-2 treatment and prolonged host survival.
Materials and methods

Animals
Female C57BL/6 mice of 6-8 weeks old were purchased from Charles River Laboratories (Wilmington, Massachusetts, USA). Mice genetically deficient for TLR7, TLR9, and MyD88, were gifts from S. Akira (Osaka University, Osaka, Japan) and were backcrossed 10 generations onto the C57BL/6 background. All procedures and protocols were approved by the UCSD Institutional Animal Care and Use Committee.
Reagents
TLR7 agonists, 1V199 and 1V209, were synthesized as described earlier [20] . 1V199, is an NHS ester derivative of 1V209, which can couple with molecules containing a primary amine group in situ. Ovalbumin (OVA, grade V, Sigma-Aldrich, St Louis, Missouri, USA) 0.17 mg/ml was incubated with an excess amount of 1V199 (1.62 mmol/l) for 4 h at 371C. Coupling chemistry was verified by a mobility shift from native OVA by SDS-polyacrylamide gel electrophoresis. Phospholipid and phospholipid-PEG were conjugated to 1V209 as described [20] . Stock solutions of 1 mmol/l were stored in dimethyl sulfoxide at -201C until use. IL-2 was obtained from the NCI Preclinical Repository (Frederick, Maryland, USA). Endotoxin levels in all reagents and conjugates were less than 1 pg/ng compounds as measured by the QCL1000 end point chromogenic Limulus Amoebocyte Lysate assay, (BioWhittaker, Walkerville, Maryland, USA) or as otherwise described. H-2K b -restricted OVA peptide (NH 2 -SIINFEKL-COOH) was purchased from GeneScript (Piscataway, New Jersey, USA). Phycoerythrin-conjugated H-2K b OVA tetramer-SIINFEKL-PE (OVA-tetramer) was obtained from the National Institutes of Health Tetramer Core Facility (Atlanta, GA).
In-vitro cytokine release assays
Bone marrow derived dendritic cells (BMDC) were prepared as described earlier [21] . BMDC (1 Â 10 5 /mL) were incubated with unconjugated TLR7 agonists or TLR7 agonist conjugates for 24 h. Levels of IL-6 and IL-12 in the supernatant were measured by enzyme linked immunosorbent assay (BD Pharmingen, San Diego, California, USA).
Tumor models
B16 melanoma tumor cells expressing the transgene for cOVA (B16cOVA) were obtained from American Type Culture Collection (Manassas, Virginia, USA) and cultured in Dulbecco's modified Eagle's medium (Irvine Scientific, Irvine, California, USA) supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/l of L-glutamine, and 100 u/ml penicillin and 100 mg/ml streptomycin. Female C56BL/6 mice of 6-8 weeks old were subcutaneously injected with 1-2 Â 10 5 B16cOVA in the flank. Primary tumors usually became palpable on day 7 and with an average diameter of 3 mm. On day 7, lesions were injected as indicated in the figure legends with a single dose or multiple doses of 50 ml solution containing TLR7 agonists or vehicle in dimethyl sulfoxide. IL-2 (20 000 units per mouse) was intraperitoneally injected twice a day on days 7, 8, 9, 10, and 11. Five to 22 mice per group were used. The number of mice in each individual study is described in the figure legends. Tumors were measured every other day. The tumor volumes were estimated according to the formula: volume (mm 3 ) = (length) Â (width) 2 Â 0.5. Mice were followed for survival and were killed at a maximum tumor diameter of 1.0 cm.
Cytotoxic T cell assay
Cytotoxic T cell (CTL) activity was assayed as described earlier [22] . Briefly, 3.5 Â 10 6 /ml of effector splenocytes were restimulated in culture for 5 days with 3 Â 10 6 /ml of OVA peptide-pulsed stimulator splenocytes and 10 u/ml of recombinant human IL-2 (Sigma) in RPMI1640 supplemented with 10% fetal bovine serum. After restimulation, viable lymphocytes were recovered and washed. The recovered effector cells were incubated with target cells pulsed earlier with OVA peptide or control cells. After 4 h the supernatants were recovered and lysis was assayed by lactate dehydrogenase release with the CytoTox 96 kit (Promega, Madison, Wisconsin, USA) according to the manufacturer's instructions.
Fluorescent flow cytometry
A single cell suspension was prepared from spleens and draining lymph nodes using Hank's buffered salt solution containing 5 mg/ml of collagenase I and 20 mg/ml of DNase I for 1 h at room temperature. The cells were stained for CD4, CD8, or OVA-tetramer. Flow cytometry analysis was carried out using FACSCalibur cytometer (BD Biosience), and the data were analyzed using FlowJo software (Ashland, Oregon, USA).
Histological examination
Hematoxylin and eosin and immunohistochemical stainings were done by UCSD Cancer Center Histology and Immunohistochemistry Shared Resources. Briefly, subcutaneous tumors from killed mice were removed, fixed in formalin, and embedded in paraffin. Sections of 5-mm thick tumors were stained with hematoxylin and eosin. For immunohistochemical staining, the 5-mm frozen sections were incubated with biotinylated anti-CD11c or anti-F4/80 antibodies followed by alkaline phosphatase-conjugated streptavidin, Vector Blue substrate, and nuclear fast red counterstain (Vector Laboratories Inc., Burlingame, California, USA). The sections were examined under the microscope at Â100 or Â 200 magnification.
Statistical analysis
Data were plotted and fitted by nonlinear regression assuming a Gaussian distribution with uniform standard deviations between groups. The statistical differences for multiple comparisons were analyzed by two-way analysis of variance with Bonferroni's or Dunnett's post hoc test. Kaplan-Meier survival curves were assessed by log rank tests. All analyses were carried out using Prism software (version 4.0, GraphPad Software Inc., San Diego, California, USA). A value of P value of less than 0.05 was considered statistically significant.
Results
Subcutaneous B16cOVA melanoma nodules expand rapidly in TLR7-deficient mice Although pharmacologic activation of innate immunity by stimulating TLRs has been proposed for immunotherapy of melanoma [23, 24] , there is little information regarding the importance of stromal TLRs in melanoma growth. To study the role of TLR7 in the tumor microenvironment, B16cOVA cells in the early logarithmic growth phase were subcutaneously implanted into wild type (WT) mice or mice that were genetically deficient for TLR7, TLR9, or MyD88. Nodule growth was monitored and mice were killed at the time the tumor reached 1 cm in any dimension, which was considered to be the survival endpoint. The median time to kill WT, TLR7 -/ -, TLR9 -/ -, and MyD88 -/mice was 20, 20, 22, and 19 days, respectively ( Fig. 1a ). Although both TLR7 and TLR9 signal through MyD88, the growth pattern for nodules diverged between these host strains. There was a trend toward faster tumor growth in the TLR7 -/and MyD88 -/mice, compared with the control mice, whereas tumor growth was slightly delayed in the TLR9 -/mice. Notably, the tumor growth in TLR7 -/mice was significantly faster than in WT mice (P < 0.05).
As a part of innate immune function, the TLR-MyD88 signaling pathway activates macrophages and participates in their recruitment to the sites of inflammation.
Potentially the impaired TLR function in the genetically targeted mice could have reduced inflammatory cell recruitment that created a more permissive environment for tumor cell growth. On day 10, tumors were removed from each strain of mice when their size reached about 3-4 mm diameter and were examined histologically. Unexpectedly, the immune cell infiltration seemed to be similar in all groups of mice ( Fig. 2c ).
Repeated intratumoral injections with a TLR7 agonist reduces B16cOVA growth
The studies above indicated that the MyD88 pathway in the stromal or infiltrating inflammatory cells might play a role in suppressing the rapid expansion of tumor nodules. Accelerated nodule growth was seen in the TLR7 -/mice, but not in the TLR9 -/mice, implying that TLR7-specific stimulation in the tumor microenvironment might attenuate melanoma cell growth (Fig. 2b) . Hence, we administered a TLR7 agonist, 1V199, directly into the tumor site using either a single high dose regimen or a repeated low dose protocol (Fig. 3a, b ). In the first protocol, 1V199 was injected into day-7 established subcutaneous tumors at a single high dose (11 nmoles/injection, high single; Fig. 3a) ; in the second, low doses (2.2 nmoles/injection) of 1V199 were administered every other day for two weeks (low multiple; Fig. 3a ). Repeated injections of low dose of 1V199 significantly inhibited the tumor growth (P < 0.03 on day 17) compared with the vehicle-treated mice (Fig. 3a) and improved survival of the recipients (28 days), compared with vehicle alone (19 days, P < 0.025, Fig. 3b ). In contrast, a single injection of high dose 1V199 (11 nmoles/ injection) neither significantly altered the tumor growth nor the survival.
The NHS ester on 1V199 can covalently bind to the primary amines on the solvent-exposed surfaces of proteins under physiological conditions (Fig. 1 ). We hypothesized that insitu conjugation to tumor associated antigens might enhance the antiproliferative effects of this TLR7 agonist. To test this hypothesis, 1V209, the carboxylic acid derivative, which is not able to couple to amines, was synthesized [20] . Using the multiple low dose treatment strategy, B16cOVA nodule bearing mice received multiple intratumoral injections of 1V199 or 1V209 (2.2 nmoles/injection) on days 7, 9, 11, 13, 15, 17, and 19 (Fig. 3c ). Median survival of mice treated with 1V209 was 20 days, similar to the vehicletreated control mice, whereas median survival of the mice treated with 1V199 was 28 days, significantly different from the control mice (P = 0.016 in Fig. 3c ).
Intralesional injection of a TLR7 agonist-phospholipid conjugate prolongs survival in mice with melanoma nodules
Earlier, we reported that conjugation of lipids, phospholipids, and PEG to TLR7 agonists could provide distinct immunostimulatory activities in vitro and in vivo [20] . These conjugates are TLR7 specific, and potently stimulate cytokine release from bone marrow derived macrophages and human peripheral blood mononuclear cells [20] . The use of PEG spacers between the TLR agonist and the phospholipid (1V285) improved aqueous solubility. In contrast, the phospholipid conjugate (1V270) acted as a depot, delivering the TLR7 activator over a more prolonged period [20] . Other earlier reports suggested that the antitumor effects of topical TLR7 ligands could be mediated by infiltrating dendritic cells [25, 26] . Hence, we tested the ability of the conjugated compounds to stimulate the production of IL-6 and IL-12 by BMDC ( Fig. 4a, b) . The phospholipid-TLR7 agonist or PEG-phospholipid TLR7 agonist conjugates (1V270 and 1V285) were 10 to 100 times more potent than unconjugated form (1V199) (Fig. 4a, b) .
We further tested the in-vivo efficacy of these compounds in the melanoma model. Established subcutaneous melanoma nodules were injected with the unconjugated form of the TLR7 agonist (1V199), the phospholipid-TLR7 agonist (1V270), or the PEGphospholipid-TLR7 agonist (1V285) on days 7, 9, 11, 13, 15, 17 and 19 . The survival times of animals treated with 1V199 or 1V270 were significantly better than the vehicle-treated mice (P = 0.01 and P = 0.001, respectively, Fig. 4c ). Treatment with 1V199 or 1V270 significantly inhibited tumor growth compared with vehicle-treated animals (P < 0.05, on days 15 and 17). In contrast, the administration of the PEG-phospholipid-TLR7 agonist (1V285) influenced neither the tumor growth nor the survival (Fig. 4c, d) . The tumor growth curves were terminated on the day the first mouse was killed, to prevent skewing the data in favor of smaller tumor sizes in the surviving mice. The antitumor effects of 1V270 were abrogated in the MyD88 -/mice, indicating that the effect of the treatment was dependent on the MyD88 signaling pathway (Fig. 4e) . The antimelanoma effect of 1V270 was also observed in the mice bearing B16-F0 melanoma, which does not express an OVA transgene (data not shown). Collectively, the data indicate that the phospholipids-conjugated TLR7 agonists suppressed the melanoma growth and prolonged the survival more effectively than the unconjugated TLR7 agonist, 1V199, in this mouse model. For advanced, unresectable melanoma, standard therapy with agents such as dacarbazine, temozolomide, and IL-2 is associated with notoriously low response rates. Both major histocompatibility complex and non-major histocompatibility complex mechanisms of action have been proposed for IL-2 [27, 28] . We, therefore, tested the combination treatment of systemic high-dose of IL-2 that may act on effector cells of the innate immune system and local intratumor TLR7 agonist (Fig. 5a ). Treatment with either IL-2 or phospholipid-TLR7 agonist conjugate (1V270) significantly reduced the tumor growth (P < 0.05 compared with vehicle treated on day 15, respectively, Fig. 5b ). However, the median survival of mice treated with IL-2 and 1V270 were 19 and 21 days, respectively, similar to the vehicle-treated group (17 days, Fig. 5a ). Combination therapy suppressed tumor growth significantly by days 13 and 15 (P < 0.01 and P < 0.001, respectively), and extended survival to 26 days.
Combination therapy with IL-2 and local treatment of 1V270 enhances CD8 + T cell responses
To examine the inflammatory infiltrate in the mice treated as outlined above, the tumor nodules were removed on day 16 and prepared for histological staining. The nodules were stained for dendritic cell (CD11c), macrophage (F4/80), and T cell (CD4 and CD8) markers. Qualitatively there were minimal differences in the staining patterns between all the groups on day 16. These data suggested that the treatment did not affect cellular recruitment into the tumor but had a separate effect on cellular function.
We further studied the effects of combination therapy on CTL expansion and activity. The cells isolated from draining lymph nodes were examined for CD8 and OVA-specific tetramer binding. Treatment with 1V270, or the combination of 1V270 and IL-2 increased the frequency of tetramer-specific CD8 + T cells (Fig. 6b ). Furthermore, the cytotoxic activity of OVA-specific T cells was examined using a CTL assay using in-vitro restimulated splenocytes. Splenocytes harvested from mice that received the combination of 1V270 and IL-2 exhibited greater OVA specific cytotoxicity in vitro (P < 0.05 compared with vehicle-treated or 1V270-treated group, Fig. 6c ).
Discussion
The current standard of care for patients with unresectable malignant melanoma is either single agent chemotherapy or high dose IL-2 [29] . Dacarbazine, the only FDA approved chemotherapy for melanoma, has a response rate of below 10% and lacks data showing an improvement in overall survival over the best supportive care [2] . Bolus high-dose IL-2 therapy can lead to longterm complete remission in a minority of patients [3] . The occasional dramatic response to cytokine therapy and the immune selection observed during disease progression has lead to the belief that melanoma may be treatable by immune therapy, and recent clinical trials with antibodies to the immunosuppressive molecule CTLA4 support this conclusion. Here the early suppression of growth in B16cOVA nodules in WT mice compared with MyD88 -/mice suggested that enhancing innate immune function might work as an adjunct in immune based therapies. (a) To augment the efficacy of utilizing TLR7 agonists as an adjunct to chemotherapy or other immunologic therapies, we developed a series of compounds that were conjugated to phospholipids or phospholipids-PEG. In an earlier report, we showed that these compounds retained their TLR7 specificity and stimulated macrophages and dendritic cells to release cytokines [20] . These compounds also stimulated release of inflammatory cytokines in vivo and are effective adjuvants. Although imiquimod is FDA approved and has some topical efficacy, we hypothesized that conjugation of a more potent TLR7 activator to a phospholipid would sustain innate immune activation. Alternatively, the conjugation of drugs to PEG can increase water solubility and may improve delivery for some applications [30] .
The phospholipid and phospholipid-PEG conjugated TLR7 agonists did stimulate cytokine release from cultured dendritic cells. However, the phospholipid-PEG conjugated drug did not suppress tumor growth in vivo, suggesting that increasing the water solubility of the compound reduced its subcutaneous efficacy. Conversely, the phospholipid-conjugated drug was the most potent in reducing nodule growth, indicating possible prolonged TLR7 activation. It is likely that the conjugation prolonged the presence of the drug in the tissue, sustaining its activity in a depot form. Alternatively, conjugation to the phospholipid might have improved cellular permeability and delivery of the TLR7 activator to the endosome. This is biologically essential, as TLR7 and TLR9 are only active after proteolytic cleavage and transport to the endosome [31, 32] . Hence, the intracellular uptake and trafficking of the compound to the endosome would be key to sustaining the activity.
Although IL-2 therapy has the potential to induce a prolonged remission in melanoma, the side effects of the agent are often not well tolerated [3] . Adjunctive therapy that would allow lower doses of IL-2 to achieve remission would be valuable. The addition of an innate immune activator, however, has the potential for additive systemic cytokine-associated toxicity. Systemic administration of a TLR7 agonist has been shown to be well tolerated in humans, and in a small number of patients with chemotherapy refractory melanoma there was stabilization of disease [33] . Hence, a continued optimization of lead candidates in this area is warranted.
Although melanoma cells can express TLR7, it is not likely that the antitumor effect was mediated solely by direct activation of the tumor cells [34] . The stromal cells in the periphery and local innate immune cells were also likely stimulated by the drug, enhancing the activity. Topical TLR7 activation recruits dendritic cells and increases the capacity of antigen-presenting cells to induce reactive T cells. Here we showed that the combination of systemic IL-2 and local TLR7 agonist increased the frequency of antigen specific T cells and enhanced CTL activity. There have recently been reports that topical TLR7 can act as an adjuvant in enhancing antitumor responses [7, 25, 33, 35, 36] . Although the adjuvanticity of the TLR7 conjugates was not formally tested in this report, we earlier found that agonists conjugated to albumin or to phospholipid caused rapid elevation of immunoglobulin G2a antibodies [20] . Mice immunized with the phospholipid conjugates and antigen developed sustained antigen-specific immunoglobulin G2a levels and interferon-g splenocyte responses without further boosting [20] . Hence, conjugation of a TLR7 agonist to phospholipid moieties is a promising strategy for topical or intralesional application, which could augment antigen specific immune responses. Future experiments will investigate the potential for the phospholipid conjugates to act as an adjuvant for melanoma directed immunotherapy.
